Pathology Industry in the United States: Market Research Reports, Statistics and Analysis

Morphosys Ag - Company Report For Year 2013

... To infectious diseases. In fact, we do have a different program ongoing in the same field, mainly mrsa, so that continues that other program. So that shows you that that particular around the absynth program ...

Company Report: Pathology In The United States For Year 2013

Company Report: Pathology In The United States And Ireland For Ye ...

... Involved, even indirectly, with an important therapeutic area that addresses the needs of millions of patients who suffer from respiratory disease is particularly meaningful to all of us at elan." Relvar ...

Company Report: Pathology In The United States For Year 2013

... Stribild gilead hiv-1 infection aug. 27 Neutroval sicor biotech neutropenia aug. 29 Linzess forest ibs aug. 30 Xtandi astellas prostate cancer aug. 31 Bosulif pfizer leukemia sep. 4 Aubagio sanofi multiple ...

Company Report: Pathology In The United States For Year 2013

U.s. Pharmaceutical Business

... Annually. Diabetic foot ulcers lead to over 82,000 amputations annually at a cost that are estimated to exceed $3.6 Billion annually. Hospitalization costs of ~$20,000 for a patient with a dfu; ~$60 ...

U.s. Brain Tumor Industry (brain Tumor, Glioblastoma)

... Uncertainty was positively correlated to five poms-sf subscales, anger, confusion, depression, fatigue, and tension (all with p ...

Pharmaceutical Sector In The United States

... Such as heart attack, stroke, heart failure and end-stage kidney failure.13 cardiovascular diseases are costly to society; direct and indirect costs of cardiovascular diseases in the u.S. Are estimated ...

U.s. Pharmaceutical Industry

... Sorbentstm competition 38 no approved therapies in the eu or us to prevent or treat organ failure Sepsis Ards and ali Burn injury Trauma Severe acute pancreatitis Cardiopulmonary bypass ...